P2.06-019 A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC)
Year: 2017
Type: article
Source: Journal of Thoracic Oncology
Authors: Dwight Owen, Paul Bunn, Bruce Johnson, David Kwiatkowski, Mark Kris, Ignacio Wistuba, Mayank Gandhi, See Phan, David Shames, Katja Schulze, Coen Bernaards, Dara Aisner, Jamie Chaft, Justin Gainor, Jay Lee, John Minna, Mari Mino-Kenudson, Celia Garcia-Prieto, Valerie Rusch, Anita Sabichi, Liza Villaruz, Antoinette Wozniak, David Carbone
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Colorado Denver, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Genentech, Massachusetts General Hospital, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, The University of Texas Southwestern Medical Center, Baylor College of Medicine, University of Pittsburgh, The Barbara Ann Karmanos Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2569676502